VanEck Biotech ETF
BBH
79 hedge funds and large institutions have $249M invested in VanEck Biotech ETF in 2017 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 21 increasing their positions, 23 reducing their positions, and 9 closing their positions.
223% more call options, than puts
Call options by funds: $4.94M | Put options by funds: $1.53M
12% more capital invested
Capital invested by funds: $222M → $249M (+$26.6M)
9% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 23
5% less funds holding
Funds holding: 83 → 79 (-4)
18.06% less ownership
Funds ownership: 52.71% → 34.65% (-18%)
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$14.1M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.31M |
| 3 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$1.62M |
| 4 |
CCA
Conservest Capital Advisors
Wynnewood,
Pennsylvania
|
+$1.33M |
| 5 |
IA
IFP Advisors
Tampa,
Florida
|
+$241K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nomura Asset Management
Tokyo,
Japan
|
-$1.76M |
| 2 |
ZIM
Zacks Investment Management
Chicago,
Illinois
|
-$1.12M |
| 3 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$1.04M |
| 4 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$938K |
| 5 |
TBA
Train Babcock Advisors
New York
|
-$782K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
JCM
76
Jacobi Capital Management
Pittston,
Pennsylvania
| $8K | +$7.81K | +60 | New |
|
|
AIP
77
Ameritas Investment Partners
Lincoln,
Nebraska
| $6K | – | – | – |
|
|
QAM
78
QCI Asset Management
Pittsford,
New York
| $3K | – | – | – |
|
|
ZIM
79
Zacks Investment Management
Chicago,
Illinois
| – | -$1.12M | -1,114,205 | Closed |
|
|
80
Nomura Asset Management
Tokyo,
Japan
| – | -$1.76M | -13,986 | Closed |
|
|
TBA
81
Train Babcock Advisors
New York
| – | -$782K | -6,227 | Closed |
|
82
Capital Fund Management (CFM)
Paris,
France
| – | -$477K | -3,800 | Closed |
|
|
PCMM
83
Private Capital Management (Minnesota)
Eagan,
Minnesota
| – | -$126K | -1,000 | Closed |
|
|
FT
84
Fiduciary Trust
Boston,
Massachusetts
| – | -$124K | -984 | Closed |
|
|
AP
85
Advisors Preferred
Rockville,
Maryland
| – | -$69K | -547 | Closed |
|
|
WEC
86
Winslow Evans & Crocker
Boston,
Massachusetts
| – | -$40.8K | -325 | Closed |
|
|
NFG
87
Next Financial Group
Houston,
Texas
| – | -$13K | -100 | Closed |
|
BBH Hedge Fund Activity: Q3 2017 in Review
79 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q3 2017, worth a combined $249M — up 12% from $222M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of BBH and 6 opened new positions — a net loss of 3 holders — while 23 trimmed existing stakes and 21 added.
The largest buyer was UBS Group, adding an estimated $14.1M. The largest seller was Nomura Asset Management, exiting entirely with an estimated $1.76M sold.
- 79 institutional investors held VanEck Biotech ETF (BBH) as of Q3 2017, down from 83 in Q2 2017.
- Funds reported $249M of VanEck Biotech ETF stock for Q3 2017, up 12% quarter-over-quarter.
- 6 funds opened new VanEck Biotech ETF positions in Q3 2017 and 9 closed out, a net change of -3 holders.
- The largest VanEck Biotech ETF buyer in Q3 2017 was UBS Group, an estimated $14.1M added.
- The largest VanEck Biotech ETF seller in Q3 2017 was Nomura Asset Management, an estimated $1.76M sold.
Based on aggregated 13F filings for Q3 2017.